Prof. Lyu is the Associate Director of Hong Kong Traditional Chinese Medicine Phenome Research Center (HKPR) at School of Chinese Medicine, Hong Kong Baptist University, and the Associate Director of Guangzhou-Hong Kong-Macau Universities Joint Laboratory of Interventional Medicine. He also holds the position of Principal Investigator (PI) at the State Key Laboratory of Environmental and Biological Analysis (HKBU), the State Key Laboratory of Medical Genomics (SJTU), and Institute of Systems Medicine and Health Sciences. Prof. Lyu is the elected member of The European Academy of Sciences and Arts (Class II of 2024, Medicine) and the Fellow of the Royal Society of Chemistry (FRSC) and the Royal Society of Biology (FRSB). He is recognized as a Faculty Opinions (F1000 Prime) expert, and a visiting professorship in Haihe Laboratory of Modern Chinese Medicine (Tianjin, China). In addition, Prof. Lyu is the Chief Expert at the Shanghai Academician and Expert Workstation. Previously, Prof. Lyu was the tenured professor at the Shanghai Center for Systems Biomedicine at Shanghai Jiao Tong University. He also served as a professor and assistant dean at the Innovative Drug Research Center of the School of Pharmaceutical sciences at Chongqing University. Earlier in his career, he worked as a postdoctoral research fellow at the Albert Einstein College of Medicine, the Washington University School of Medicine, and the Massachusetts Institute of Technology (SMART Center). Prof. Lyu's research strengths focus on the transformative development of functional metabolomics strategies (STORM and STORM+), and translational applications in precision medicine research. He has successfully led more than 17 projects, including the National Key R&D Program， the National Natural Science Foundation of China, Guangdong-Hong Kong 1+1+1 Joint-Scheme, Agilent Core Technology-University Relation Award，QUT Vice Chancellor Research Fellowship, et al. His contributions to the field are evidenced by the publication of 66 SCI-indexed papers in high-profile journals, with 4 highly cited papers in the Essential Science Indicators (ESI). Prof. Lyu has co-edited one English book published by Wiley and one Chinese book on Chinese medicine innovations. Prof. Lyu serves as the Deputy Secretary-General of the Metabolomics Committee of the Chinese Society of Biophysics, The Vice Chairman of The Fangjiomics Specialty Committee of Chinese Pharmaceutical Association, the Deputy Secretary-General of the Network Pharmacology Specialty Committee of the Chinese Pharmacological Society, and The Vice Chairman of the Drug Metabolism Specialty Committee of the Guangdong Pharmacological Society. Prof. Lyu is the section editor for Pharmacological Research, the Associate Editor for Royal Society Open Science, the Associate Editor for Phytomedicine, and an editorial board member for Proteomics, and European Journal of Pharmacology. Prof. Lyu is also an expert referee for the National Natural Science Foundation of China and the Hong Kong Health and Medical Research Fund. Prof. Lyu's outstanding contributions have been recognized through several prestigious awards, including the 2021 Agilent Technologies Global Competitive ACT-UR Award, the 2022 Faculty Opinions Member of The Year Award, the 2013 QUT Vice Chancellor Research Fellowship, the 2022 APSB Outstanding Young Editorial Board Member Award, 2023 The Outstanding Editorial Board Member Award (Chinese Medicine Journal), 2024 The Outstanding Editor Award (Chinese Medicine).

Tenured Professor (Associate), Associate Director

Hong Kong Traditional Chinese Medicine Phenome Center

School of Chinese Medicine

Hong Kong Baptist University, Hong Kong, China (April 2023- )

Principal Investigator

Institute of Systems Medicine and Health Sciences

Hong Kong Baptist University, Hong Kong, China (October 2024- )

Principal Investigator

State Key Laboratory of Medical Genomics

Shanghai Jiao Tong University, Shanghai, China (August 2023- )

Professor with Tenure, PI, PhD Candidate Supervisor

Faculty Director, Laboratory of Functional Metabolomics Science

Shanghai Center of Systems Biomedicine

Shanghai Jiao Tong University, Shanghai, China (May 2016-April 2023)

Adjunct Professor, PhD Candidate Supervisor, Systems Pharmacology

Macau University of Science and Technology, Macau, China (2020-till now)

Vice Chancellor’s Fellow, PhD Candidate Supervisor, Metabolomics

Institute of Health and Biomedical Innovation, Faculty of Health

Queensland University of Technology, Brisbane, Australia (2013-2016)

Professor, PhD Candidate Supervisor, Metabolomics and Chemical Biology

Faculty Director, Central Mass Spectrometry and Omics Facility

Chongqing University School of Pharmaceutical Sciences, Chongqing, China (2013-2016)

Postdoctoral Research Scientist, Metabolomics and RNA Modifications

SMART Research Centre, Department of Biological Engineering

Massachusetts Institute of Technology, Singapore and Cambridge, USA (2012-2013)

Postdoctoral Research Associate, Metabolomics and Microbiology

Department of Molecular Microbiology, Center for Women's' Infectious Diseases Research

Washington University School of Medicine, Saint Louis, USA (2010-2012)

Postdoctoral Research Fellow, Metabolomics and Metabolic Biology

Diabetes Research and Training Center, Department of Medicine

Albert Einstein College of Medicine, New York, USA (2009-2010)

    香港浸會大學中醫藥學院呂海濤教授/課題組長/博士生導師，歐洲科學與人文學院院士，英國皇家化學會會士，英國皇家生物學會會士，河南省人民政府特聘研究員（海外），香港中醫藥表型組學研究中心副主任，介入醫學粵港澳高校聯合實驗室副主任，環境與生物分析國家重點實驗室課題組長, 疾病與組學全國重點實驗室課題組長，澳門科技大學兼職教授/博士生導師，現代中醫藥海河實驗室客座教授，上海院士專家工作站（專家級）首席專家，世界五百強丹納赫集團中國生命科學委員會顧問專家。曾任上海交通大學長聘教授/功能代謝組科學實驗室主任，重慶大學藥學院百人計劃研究員/助理院長（主任），美國愛因斯坦醫學院，華盛頓大學醫學院和麻省理工學院博士後研究員。長期從事生命健康交叉科學應用驅動的下一代功能代謝組學方法與策略創新，及其轉化應用於復雜疾病精準診療和創新藥物研發。主持國家重點研發計劃，國家自然科學基金和粵港高校1+1+1聯合資助計劃，Agilent Core Technology-University Relation Award，QUT Vice Chancellor Research Fellowship等17項基金，權威雜誌發表SCI論文66篇，ESI高被引4篇。任中國藥學會方劑組學專委會副主任委員、中國藥理學會網絡藥理學專委會副秘書長，中國生物物理學會代謝組學分會副秘書長和廣東省藥理學會藥物代謝專委會副主任委員等；任Pharmacological Research-Section主編，Royal Society Open Science副主編；Phytomedicine副主編，安捷倫全球競爭性ACT-UR Award和QUT Vice Chancellor Fellowship獲得者。國家科技部重點研發計劃和重大人才計劃終審專家。

    香港浸会大学中医药学院吕海涛教授/课题组长/博士生导师，欧洲科学与人文学院院士，英国皇家化学会会士，英国皇家生物学会会士，河南省人民政府特聘研究员（海外），香港中医药表型组学研究中心副主任，介入医学粤港澳高校联合实验室副主任，环境与生物分析国家重点实验室课题组长, 疾病与组学全国重点实验室课题组长，澳门科技大学兼职教授/博士生导师，现代中医药海河实验室客座教授，上海院士专家工作站（专家级）首席专家，世界五百强丹纳赫集团中国生命科学委员会顾问专家。曾任上海交通大学长聘教授/功能代谢组科学实验室主任，重庆大学药学院百人计划研究员/助理院长（主任），美国爱因斯坦医学院，华盛顿大学医学院和麻省理工学院博士后研究员。长期从事生命健康交叉科学应用驱动的下一代功能代谢组学方法与策略创新，及其转化应用于复杂疾病精准诊疗和创新药物研发。主持国家重点研发计划，国家自然科学基金和粤港高校1+1+1联合资助计划，Agilent Core Technology-University Relation Award，QUT Vice Chancellor Research Fellowship等17项基金，权威杂志发表SCI论文66篇，ESI高被引4篇。任中国药学会方剂组学专委会副主任委员、中国药理学会网络药理学专委会副秘书长，中国生物物理学会代谢组学分会副秘书长和广东省药理学会药物代谢专委会副主任委员等；任Pharmacological Research-Section主编，Royal Society Open Science副主编；Phytomedicine副主编，安捷伦全球竞争性ACT-UR Award和QUT Vice Chancellor Fellowship获得者。国家科技部重点研发计划和重大人才计划终审专家。

Role: Chief Investigator (Dr. Haitao Lu)

MEMBERSHIP OF LEARNED SOCIETIES

Since 2024, Elected Member, European Academy of Sciences and Arts

Since 2024, Distinguished Professorship of Henan Province, China

Since 2022, Scientific Advisory Expert, Danaher Life Sciences China

Since 2021, Elected Fellow (FRSC), The Royal Society of Chemistry in UK

Since 2021, Elected Fellow (FRSB), The Royal Society of Biology in UK

Since 2019, Vice Secretary General, Metabolomics-Biophysical Society of China

Since 2021, Faculty Member, Faculty Opinions Prime (Former F1000 Prime)

Since 2021, Chief Scientist, Shanghai Platform for Academicians and Experts

Since 2021, Committee of Chinese Medicine Immunology, WFCMS

Since 2010, American Association of the Advancement of Science

Since 2010, Metabolomics Society

EDITORIAL BOARD MEMBER OF REFERRED JOURNALS

Since 2020, Pharmacological Research (Section Editor)

Since 2025, Phytomedicine (Associate Editor)

Since 2018, Acta Pharmaceutica Sinica B (EBM)

Since 2019, Proteomics (EBM)

AWARDS AND FELLOWSHIPS

2025   Recipient of 2025 Springer Nature Award of Editorial Distinction Contribution 

2024   Recipient of 2024 Award of Outstanding Editor of Chinese Medicine (Q1)

2022   Recipient of 2022 Faculty Opinions Faculty of The Year Award

2022   Recipient of 2022 Award of Excellence for Editorial Board Member

of Acta Pharmaceutica Sinica B (Q1, TOP)

2021   Recipient of Agilent-Tech Global-Competitive ACT-UR Award

2013   The Vice Chancellor’ Research Fellowship Provided by QUT  

PEER REVIEWER OF FUNDING AGENCY

Since 2021, Health and Medical Research Fund (HMRF) in Hong Kong, China

Since 2020, Ministry of Science and Technology, People’s Republic of China

Since 2013, National Natural Science Foundation of China

Since 2016, National Health and Medical Research Council (NHMRC) in Australia